Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan’s RetroSense Buy Marks Move Into Gene Therapy

Executive Summary

The company agreed to pay $60m upfront to buy privately-held RetroSense, the developer of a novel gene therapy in Phase I/II clinical testing for retinitis pigmentosa. The investment in early R&D helps Allergan catch up with other eye care research.

Advertisement

Related Content

Editas Deal Opens Allergan's Eyes To CRISPR Opportunities
‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy
Allergan Sees Growth From New Launches, Not Big M&A
Venture Funding Deals, February 2015

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel